Bruker BioSciences to Present at UBS Global Life Sciences Conference; Live Webcast on Wednesday, September 28th at 11:30 AM East
23 September 2005 - 9:00PM
Business Wire
Bruker BioSciences Corporation (Nasdaq: BRKR) today announced that
it will join other leading life sciences companies in presenting at
the UBS Global Life Sciences Conference taking place September
26-29 in New York. Bruker BioSciences Corporation's President and
CEO, Frank Laukien, will present an overview of the Company,
including an update on recent developments, recently-announced
product innovations, and expectations. He will be accompanied by
Chief Financial Officer William J. Knight. Dr. Laukien's
presentation will be webcast live at 11:30 AM Eastern Time (8:30 AM
Pacific Time) on Wednesday, September 28, 2005 from the Grand Hyatt
Hotel in New York. The webcast can be accessed on Bruker
BioSciences' website at www.bruker-biosciences.com with playback
available until October 28. ABOUT BRUKER BIOSCIENCES Bruker
BioSciences Corporation, headquartered in Billerica, Massachusetts,
is the publicly traded parent company of Bruker AXS Inc. and Bruker
Daltonics Inc. Bruker AXS is a leading developer and provider of
life science and advanced materials research tools based on X-ray
technology. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. For more
information, please visit www.bruker-biosciences.com CAUTIONARY
STATEMENT Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's reorganization strategies,
integration risks, failure of conditions, technological approaches,
product development, market acceptance, cost and pricing of the
Company's products, changes in governmental regulations, capital
spending and government funding policies, FDA and other regulatory
approvals to the extent applicable, competition, the intellectual
property of others, patent protection and litigation. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual
report on Form 10-K, our most recent quarterly reports on Form 10-Q
and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024